| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e05e27db3e85d78d34b60ce4ea652ddd |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2420-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-34 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-28 |
| filingDate |
2000-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d903c383521ffce36261b8cdffd5fbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68cdd5532b746f498c34edae63d044e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_294cc5e94b6981f901d79a726fd72b77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e720deaa041d6a26117de660f7206f2a |
| publicationDate |
2002-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1180013-A1 |
| titleOfInvention |
Local drug delivery |
| abstract |
An implant having a coating comprising a polymer matrix is swollen in a pharmaceutical solution whereby pharmaceutically active compound is imbibed into the polymer matrix. When the product is implanted, release of the pharmaceutically active compound from the coating takes place. The polymer is preferably formed from ethylenically unsaturated monomers including a zwitterionic monomer, most preferably 2-methacryloyloxyethyl-2′-trimethylammoniumethyl-phosphate inner salt. The monomers from which the polymer is formed may further include surface binding monomers, such as hydrophobic group containing monomers, and crosslinkable monomers, the content of which may be used to control the swellability. Preferably the implant is a stent and the coating of polymer on the exterior wall surface is thicker than the coating of polymer on the interior surface. Release of the drug may be controlled by selection of comonomers. The implant is suitably a stent for use in the cardiovascular system. |
| priorityDate |
1999-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |